^
    Back
    Association details:
    Biomarker:NCL overexpression
    Cancer:Cervical Cancer
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    J Oncol
    Title:

    Nucleolin Promotes Cisplatin Resistance in Cervical Cancer by the YB1-MDR1 Pathway

    Published date:
    04/21/2021
    Excerpt:
    Overexpression of NCL increased cervical cancer cell proliferation and attenuated the sensitivity to cisplatin...NCL was highly related with cisplatin resistance in cervical cancer.
    DOI:
    10.1155/2021/9992218